US STAR-V Trial
iSTAR Medical Shows Initial Positive Progress of US STAR-V Trial for MINIject
Pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US. Positive feedback from world-leading glaucoma surgeons involved in the trial. MINIject is the only commercially available MIGS device targeting the supraciliary space. Commercial rollout continues following European approval in 2021